The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

AZN ASTRAZENECA PLC ORD SHS $0.25




 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next

Time/Date Code Headline Source Impact
07:00 05-Dec-2016 AZN AZ completes agreement for Rhinocort Aqua rights RNS -2.94% Down
16:00 01-Dec-2016 AZN Block listing Interim Review RNS -4.13% Down
15:00 01-Dec-2016 AZN Total Voting Rights RNS -4.13% Down
07:00 22-Nov-2016 AZN AZ head and neck cancer trials resume enrolment RNS -2.63% Down
07:00 17-Nov-2016 AZN AZ out-licensing deal with Allergan completed RNS -2.06% Down
07:04 10-Nov-2016 AZN Year-To-Date and Q3 2016 Results RNS -2.01% Down
07:00 09-Nov-2016 AZN Directorate Change RNS -0.79% Down
15:30 01-Nov-2016 AZN Dealing by Person Closely Associated RNS -4.86% Down
15:00 01-Nov-2016 AZN Total Voting Rights RNS -4.86% Down
13:47 31-Oct-2016 AZN AZ completes US Aralez agreement for Toprol-XL RNS -5.25% Down
16:51 27-Oct-2016 AZN AstraZeneca Head and Neck Cancer Trials RNS -6.20% Down
07:00 26-Oct-2016 AZN Positive results in AstraZeneca Lynparza trial RNS -5.80% Down
07:00 18-Oct-2016 AZN FDA accepts for review ZS-9 NDA for hyperkalaemia RNS -0.64% Down
07:00 07-Oct-2016 AZN AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US RNS +0.02% Up
07:05 04-Oct-2016 AZN AZ agreement with Aralez for Toprol-XL in US RNS +0.10% Up
07:00 04-Oct-2016 AZN AstraZeneca reports top-line EUCLID results in PAD RNS +0.10% Up
15:00 03-Oct-2016 AZN Total Voting Rights RNS -0.35% Down
07:00 03-Oct-2016 AZN MedImmune out-licenses medicine to Allergan RNS -0.35% Down
07:00 28-Sep-2016 AZN CHANGE TO ASTRAZENECA BOARD OF DIRECTORS RNS -1.30% Down
16:00 26-Sep-2016 AZN Director/PDMR Shareholding RNS -1.07% Down

 Page 1 of 6

| 1 | 2 | 3 | 4 | 5 | 6 | Next



Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released
y = instrument's latest 7 closing prices before the news was released, including the day of the release of the news

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank “ - “ next to the line indicating the RNS issue.





Company Information
Updated Monthly
Company address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom
Company website http://www.astrazeneca....
Market cap(in millions)* £ 50,900.69
Listing/Admission to trading 01 Jun 1993
Trading service SETS
Market Main Market
Listing category Premium Equity Commercial Companies
*The market capitalisation of companies reflects the London listed element only. These figures are approximate and are updated monthly.

Trading Information
06-Dec-16
FTSE index FTSE All-Share,FTSE Eurotop 300,FTSE 350 High Yield,FTSE 100,FTSE 350 (ex IT),FTSE techMARK All-Share,FTSE All-Share (ex IT),FTSE 350
FTSE sector Pharmaceuticals & Biotechnology
FTSE sub-sector Pharmaceuticals
Country of share register GB
Segment SET0
MiFID Status Regulated Market
Exchange market size 500
SEDOL 0989529
ISIN number GB0009895292



ASTRAZENECA share news analysis (AZN)